Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 13/20 | 0.68 |
| ▸ | RARB | P10826 | 11/20 | 0.68 |
| ▸ | RARG | P13631 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | BLVRB | P30043 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363055 | 0.82 | RARA (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8902592 | 0.81 | RARA (0.67) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL4757231 | 0.81 | RARA (1.00) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL4654688 | 0.80 | RARA (0.72) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL6292558 | 0.78 | RARA (0.69) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL8771715 | 0.78 | RARA (0.77) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL4652495 | 0.78 | RARA (0.68) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL6292560 | 0.78 | RARA (0.68) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL8981738 | 0.77 | RARA (0.76) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL4653891 | 0.76 | RARA (0.81) | RARARARBRARGKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6818775-B2 | TREATMENT OF SKIN-RELATED DISEASES OR PREVENTION OF CERTAIN UNDESIRED SIDE EFFECTS OF ADMINISTERED RETINOIDS | ALLERGAN, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | JOHNSON ALAN T (US) | 2004-07-01 | — | — | US | disclosed |
| EP-0915825-B1 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720425-B2 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6653483-B1 | Skin, neurodegenerative and cardiovascular disorders; anticarcinogenic, antiinflammatory, and antiproliferative agents | ALLERGAN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6555690-B2 | 4-((5,5-dimethyl-5,6,7,8-tetrahydro-8-hydroxynaphthalen-2 -yl)carbonyloxy)benzoic acid, benzyl ester for example; receptor subtype selectivity for side effect reduction | ALLERGAN, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-11-21 | — | — | US | disclosed |
| US-6117987-A | ANIMAL GROWTH REGULATOR; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6051731-A | TREATING SKIN DISORDERS, CANCERS, EYE DISORDERS, CARDIOVASCULAR DISORDERS, ELIMINATE OR REDUCE SIDE EFFECTS OF RETINOIDS, OR TO TREAT RETINOID OR VITAMIN A OVERDOSE OR POISONING | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5998655-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN, INC. | 1999-12-07 | — | — | US | disclosed |
| EP-0915825-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5808124-A | BINDING TO RETINOID RECEPTORS | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5773594-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF OTHER RETINOIDS | ALLERGAN (US) | 1998-06-30 | — | — | US | disclosed |
| US-5763635-A | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-06-09 | — | — | US | disclosed |
| US-5747542-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1998-05-05 | — | — | US | disclosed |
| US-5741896-A | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-04-21 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.